6 cytochrome P450 activity (Cyp3A4) and glycogen storage (16, 18) . However, HLCs 1 resemble more closely fetal rather than adult hepatocytes, with ongoing expression 2 of fetal markers (AFP) and embryonic P450 activity (Cyp3A7) ( Table 1) .
3
The fetal identity of HLCs has given rise to a plethora of studies focusing on 4 increasing their functionality. Among these approaches two main strategies emerge:
5
The first concentrates on increasing differentiation efficiency, promoting maturation 6 or enhancing P450 activity and drug metabolism. The use of small molecule 
12
(23) have all been reported to contribute towards achieving this goal. Therefore, it is 13 possible that such methodologies will increasingly complement growth factors driven 14 differentiation of hIPSCs in the future.
15
The second strategy focuses on accurately simulating the liver microenvironment to low levels of serum and alveolar A1AT, which is associated with panlobular 6 emphysema from over-active proteases such as pulmonary neutrophil elastase.
7
Retention of misfolded A1AT polymers within the hepatic endoplasmic reticulum (ER) 8 results in hepatic dysfunction and liver disease (34). A1AT deficiency was the first 9 hepatic disorder to be modelled in vitro using hIPSCs, by differentiating patient-10 derived hIPSCs into A1AT polymer-retaining HLCs. The disease phenotype was 11 confirmed by ELISA and immunocytochemistry for the polymeric form of A1AT, as 12 well as ER-specific enzyme digests, which indicated entrapment of A1AT in the ER.
13
In a subsequent study, the same group reported rescue of the disease phenotype,
14
following correction of the SERPINA1 mutation using zinc finger nucleases, thereby 15 demonstrating a direct association between the phenotype observed and the 
21
HLCs can be infected using infected patient sera (47,49). Interestingly, using HLCs, 
3
Importantly, a similar approach could be applied for the study of other common liver 4 pathogens, including HBV (51) or parasitic infections (52).
6
The potential of hIPSCs for modeling complex liver disease 7
With the exception of HCV, all liver diseases modeled to date using hIPSCs 8 constitute rare monogenic metabolic disorders that collectively account for less than
9
10% of the total number of liver transplantations performed (2) ( Table 2) . Therefore,
10
a major challenge for regenerative medicine in hepatology is evolving from proof-of-
11
principle models to modeling more complex disorders that constitute leading causes
12
for chronic liver disease and transplantation. Table 2 8
Contribution of hIPSCs to modeling liver disease. Key hepatic disorders leading to 9 liver transplantation and relevant hIPSC-based models currently available.
